DUB Inhibitors

Cat.No.	Product Name	Information	Product Use Citations
S7130	PR-619	PR-619 is a non-selective, reversible inhibitor of the deubiquitinylating enzymes (DUBs) with EC50 of 1-20 μM in a cell-free assay. This compound activates autophagy.	Cancer Immunol Res, 2025, 10.1158/2326-6066.CIR-24-1194 J Orthop Surg Res, 2025, 20(1):220 Sci Adv, 2025, 11(38):eadw2539
S7132	P5091 (P005091)	P5091 is a selective and potent inhibitor of ubiquitin-specific protease 7 (USP7) with EC50 of 4.2 μM and the closely related USP47.	Mol Metab, 2025, 94:102111 Neoplasia, 2025, 66:101192 J Exp Clin Cancer Res, 2024, 43(1):28
S7134	IU1	IU1 is a cell-permeable, reversible and selective proteasome inhibitor of human USP14 with IC50 of 4.7 μ M, 25-fold selective to IsoT. This compound induces autophagy.	Molecular Medicine, May 2, 2025, 163 Translational Andrology and Urology, February 11, 2026, 55 Cell Death & Disease, August 21, 2021, 803
S7133	P22077	P22077 is an inhibitor of ubiquitin-specific protease USP7 with EC50 of 8.6 μM, also inhibits the closely related USP47.	Int J Mol Sci, 2024, 25(5)2768 Hepatol Commun, 2024, 8(4)e0405 Queen's University Belfast, 2023,
S4920	b-AP15	b-AP15 (NSC687852) is a deubiquitinases inhibitor for 19S proteasomes activity of Ub-AMC cleavage with IC50 of 2.1 μM.	Nat Cell Biol, 2025, 27(9):1448-1464 J Control Release, 2025, 380:417-432 Int J Biol Sci, 2025, 21(5):2258-2274
S7529	ML323	ML323 displays reversible, nanomolar inhibitory activity and excellent selectivity toward USP1/UAF1 with IC50 of 76 nM.	Cancers (Basel), 2025, 17(17)2864 Oncol Res, 2025, 33(1):213-224 Nucleic Acids Res, 2024, gkae785
S7135	LDN-57444	LDN-57444 is a reversible, competitive proteasome inhibitor for Uch-L1 with IC50 of 0.88 μM, 28-fold selectivity over isoform Uch-L3.	Stem Cell Res Ther, 2025, 16(1):271 J Transl Med, 2024, 22(1):478 Cells, 2024, 13(9)737
S7140	TCID	TCID is a DUB inhibitor for ubiquitin C-terminal hydrolase L3 with IC50 of 0.6 μM, 125-fold selective to L1.	Journal of Medicinal Chemistry, October 27, 2022, 13645-13659 Cellular Signalling, May 17, 2025, 111875 Nature Communications, May 16, 2025, 4564
S8288	VLX1570	VLX1570 is a competitive inhibitor of proteasome DUB activity, with an IC50 of ~10 μM in vitro.	Commun Biol, 2024, 7(1):25 Frontiers in Pharmacology, 2022, 778216 PLoS One, 2022, 17(7):e0271245
S6877	EOAI3402143	EOAI3402143 is a dose-dependent inhibitor of Usp9x, Usp24 and Usp5 that increases tumor cell apoptosis, and fully blocks or regresses myeloma tumors in mice.	Cell Reports Medicine, 2023 Apr 18, 101007 Cell Rep Med, 2023, 4(4):101007 International Journal of Biological Sciences, 2021 Jun 11, 2417-2429
S6748	ML364	ML364 is a small molecule inhibitor of the deubiquitinase USP2 with an IC50 of 1.1 μM in a biochemical assay using an internally quenched fluorescent di-ubiquitin substrate.	Journal for ImmunoTherapy of Cancer, 2026, e013498 Nat Commun, 2025, 16(1):4564 Cell Insight, 2022, 1(4):100047
S8904	USP25/28 inhibitor AZ1	AZ1 is a potent and noncompetitive dual Inhibitors of the ubiquitin-specific protease (USP) 25/28 with IC50s of 0.62 μM and 0.7 μM in Ub-RH110 assay,respectively.	Cell Death Dis, 2025, 16(1):305 Mol Oncol, 2022, 10.1002/1878-0261.13217 Cancer Sci, 2022, 113-10:3463-3475
S8967	XL177A	XL177A is a potent, selective and irreversible inhibitor of Ubiquitin specific peptidase 7 (USP7) with IC50 of 0.34 nM.	Cancer Cell, 2026, S1535-6108(25)00547-1 Queen's University Belfast, 2023, Harvard University (Dissertation), 2021, Materials and Methods section
S0515	PLpro inhibitor	PLpro inhibitor (compound 6) is a potent papain-like protease (PLpro)/deubiquitinase (DUBs) inhibitor with IC50 of 2.6 μM and EC50 of 13.1 μM that blocks SARS virus replication.	PLoS Pathog, 2023, 19(8):e1011592 bioRxiv, 2022, 2022.08.06.503039
S6883	HBX 19818	HBX19818 is a specific inhibitor of USP7 with an IC 50 of 28.1 μM.	Queens University Belfast (Doctoral Thesis), 2023, nan Queen's University Belfast, 2023,
S0399	SJB2-043	SJB2-043 is a potent USP1 inhibitor that inhibits the activity of native USP1/UAF1 with IC50 of 544 nM.	Frontiers in Pharmacology, June 04 2021, 695009 Autophagy, 2022, 1801-1821 Frontiers in Pharmacology, 2021, 695009
E1479	I-138	I-138 is an orally active, potent reversible inhibitor of USP1-UAF1 with IC50 0f 4.1 nM. This compound is structurally related to ML323 and induces the monoubiquitination of FANCD2 and PCNA in MDA-MB-436 cells and increases PCNA and FANCD2 monoubiquitination in HAP-1 USP1 WT cells.	J Biol Chem, 2025, 301(3):108190
E0392	Dubs-IN-1	Dubs-IN-1 is an active inhibitor of ubiquitin-specific proteases (USPs), with an IC50 of 0.85 μM for USP8.	Autophagy, 2022, 1801-1821
E1330	Usp22i-S02	Usp22i-S02(USP22-IN-1, compound S02) is a potent inhibitor of ubiquitin specific peptidase 22 (USP22). It showed anticancer activity by suppressing Foxp3 expression in T-regulatory cells.	Int Immunopharmacol, 2025, 153:114538
S6845	GRL0617	GRL0617 is a potent, selective and competitive noncovalent inhibitor of severe acute respiratory syndrome (SARS-CoV) papain-like protease (PLPro)/deubiquitinase with IC50 of 0.6 μM and Ki of 0.49 μM. This compound inhibits SARS-CoV viral replication in Vero E6 cells with EC50 of 15 microM and has no associated cytotoxicity.	Journal of Virology, 2024, e00855-24 J Virol, 2024, e0085524.
S6933	GEN-6776	GNE-6776 is a potent, non-covalent, selective and orally bioavailable inhibitor of USP7 with IC50 of 1.34 μM and 0.61 μM for full length USP7 and USP7 catalytic domain, respectively.	Queen's University Belfast, 2023,
S6878	GSK2643943A	GSK2643943A is an inhibitor of deubiquitylating enzyme (DUB) with IC50 of 160 nM for USP20/Ub-Rho.	Nature, 2020, 10.1038/s41586-020-2928-y
S4922	NSC 632839	NSC 632839 is not only a DUB inhibitor, but also a deSUMOylase inhibitor, it inhibits USP2, USP7, and SENP2 with EC50 of 45 μM, 37 μM, and 9.8 μM, respectively.
E5945^New	Wu-5	Wu-5 is an inhibitor of USP10 that blocks its activity in vitro with an IC50 of 8.3 µM. It also promotes FLT3-ITD degradation and synergistically enhances crenolanib-induced apoptosis.
E1633	BAY-805	BAY-805 is a potent, selective, and cell-active inhibitor that non-covalently targets the catalytic activity of USP21, a member of the ubiquitin-specific protease (USP) subfamily of deubiquitinating enzymes (DUBs).
E6502^New	USP7-IN-1	USP7-IN-1 (Example 2) is a selective and reversible inhibitor of USP7 with an IC50 of 77 Μm and exhibits antiproliferative activity, inhibiting the growth of HCT116 colorectal cancer cells with a GI50 of 67 μM.
E5999^New	CT1113	CT1113 is a potent dual inhibitor of USP25 and USP28 that effectively reduces c-MYC levels and exhibits strong anti-tumor activity. It can be used in research on colon and pancreatic cancers.
E1098	MF-094	MF-094, a potent and selective USP30 inhibitor (IC50=0.12 μM), accelerates diabetic wound healing by inhibiting the NLRP3 inflammasome.
E0389	DUBs-IN-2	DUBs-IN-2 is a potent inhibitor of USP7 and USP8 deubiquitinating enzymes.
E0947	Iu1-248	Iu1-248, a derivative of IU1, is a potent and selective ubiquitin specific peptidase 14 (USP14) inhibitor with an IC50 of 0.83 μM.
E1118^New	SJB3-019A	SJB3-019A is a potent inhibitor of USP1 that significantly suppresses cell proliferation and induces apoptosis in B-cell acute lymphoblastic leukemia (B-ALL) cells. It also promotes DNA-binding-1 (ID1) degradation in K562 cells.
S6943	IU1-47	IU1-47 is a potent and specific inhibitor of USP14 with an IC50 of 0.6 μM. This compound shows ∼33-fold selectivity for USP14 over USP5 (IsoT).
E6671^New	CMPD-39	CMPD-39 (Compound 39) is a selective non-covalent inhibitor of USP30 with an IC50 of ~20 nM in in vitro enzyme assays.
S0884	RA-9	RA-9 is a cell-permeable, potent and selective inhibitor of proteasome-associated deubiquitinating enzymes (DUBs) with favorable toxicity profile and anticancer activity. This compound selectively induces apoptosis in ovarian cancer cell lines.
S2913	BAY 11-7082 (BAY 11-7821)	BAY 11-7082 (BAY 11-7821) is a NF-κB inhibitor, inhibits TNFα-induced IκBα phosphorylation with IC50 of 10 μM in tumor cells. BAY 11-7082 inhibits ubiquitin-specific protease USP7 and USP21 with IC50 of 0.19 μM and 0.96 μM, respectively. BAY 11-7082 induces apoptosis and S phase arrest in gastric cancer cells.	ACS Nano, 2025, 19(20):19057-19079 Adv Sci (Weinh), 2025, 12(28):e2502634 J Med Virol, 2025, 97(8):e70534
S2243	Degrasyn (WP1130)	Degrasyn (WP1130) is a selective deubiquitinase (DUB: USP5, UCH-L1, USP9x, USP14, and UCH37) inhibitor and also suppresses Bcr/Abl, also a JAK2 transducer (without affecting 20S proteasome) and activator of transcription (STAT). This compound induces apoptosis and blocks autophagy.	Nat Commun, 2025, 16(1):628 Nat Commun, 2025, 16(1):1313 Cell Death Dis, 2025, 16(1):564
S7888	Spautin-1	Spautin-1 is a potent and specific autophagy inhibitor, and inhibits the deubiquitinating activity of USP10 and USP13 with IC50 of ∼0.6-0.7 μM. This compound enhances apoptosis.	Life Science Alliance, September 27, 2021, e202101137 Scientific Reports, July 07, 2022, 11533 OncoImmunology, February 15, 2018, e1431086
S3692	N-Ethylmaleimide (NEM)	NEM (N-Ethylmaleimide) is an organic compound that is derived from maleic acid. It is an irreversible inhibitor of all cysteine peptidases, with alkylation occurring at the active site thiol group. N-Ethylmaleimide (NEM) inactivates endogenous deubiquitinating enzymes (DUBs). N-Ethylmaleimide (NEM) specifically inhibits phosphate transport in mitochondria.	Nat Commun, 2025, 16(1):7812 Inflammation, 2025, 10.1007/s10753-025-02273-w Toxicol Lett, 2025, 406:31-37
E1214	KSQ-4279 (USP1-IN-1)	KSQ-4279 (USP1-IN-1) is an orally bioavailable selective inhibitor of the ubiquitin specific protease 1 (USP1) with anti-proliferative activity. KSQ-4279 also exhibits synergistic activity in combination with PARP inhibitors.	Cancer Res, 2024, 84(20):3419-3434 Sci Adv, 2024, 10(46):eadp6567